Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30(5):734-745.
Jolles S, Borte M, Nelson R, et al. Long-term efficacy, safety, and tolerability of Hizentra for treatment of primary immunodeficiency disease. Clin Immunol. 2014;150(2):161-169.
Data on File. Available from CSL Behring as DOF HIZ-003.
Wasserman RL, Melamed I, Nelson RP Jr, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50(6):405-414.
US Department of Health and Human Services, Centers for Medicare & Medicaid Services. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM); 2016;616-617.
American Medical Association. Medicine/hydration, therapeutic, prophylactic, diagnostic injections and infusions, and chemotherapy. In: American Medical Association, ed. CPT 2016. Chicago, IL: American Medical Association; 2016:650-651.
HCPCS Level II Expert. In: American Academy of Professional Coders. Salt Lake City, Utah: AAPC; 2016.
Murphy E, Burton J, Riley P. Nursing approaches to a novel subcutaneous immunoglobulin therapy. Infusion. 2007;13:1-8.
van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2018;17(1):35-46.